BJH - volume 8, issue 1, february 2017
D. Selleslag MD
This ASH 2016 report will focus on the diagnostic and prognostic utility of molecular abnormalities and on new treatment modalities in MDS. We selected 7 abstracts dealing with these topics.
(BELG J HEMATOL 2017;8(1):34–7)
Read moreBJH - volume 8, issue 1, february 2017
A. Bosly MD, PhD
The plenary session during the 2016 annual meeting of the American Society of Hematology featured six presentation covering different aspects of hematology. These abstracts discussed important innovations in the management of sickle cell disease, follicular lymphoma, hemophilia and ALL. In addition to this two abstracts addressed issues related to hematopoiesis.
(BELG J HEMATOL 2017;8(1):38–40)
Read moreBJH - volume 7, issue 5, october 2016
T. Feys MBA, MSc
From June 3rd till June 6th, Chicago again formed the background for the biggest cancer congress in the world. Notwithstanding the fact that solid tumours remain the main focus of the annual meeting of the American Society of Clinical Oncology (ASCO), the meeting program also included some interesting lectures on haematological malignancies. The aim of this report is not to discuss all these studies, but will address some of the key presentations on haematological cancer from ASCO 2016. For a more complete overview we would like to refer to the congress website, where all abstracts and a plethora of webcasts can be found.
(BELG J HEMATOL 2016;7(5):203–6)
Read moreBJH - volume 7, issue 4, september 2016
M. Delforge MD, PhD
Multiple myeloma (MM) is one of the haematological malignancies with the fastest therapeutic development. Consequently, interesting new data on both preclinical and clinical progress in MM were presented at the 2016 EHA meeting in Copenhagen. We have selected four clinical and one preclinical abstract for discussion in this paper. The choice is based on the importance of the presentations and the impact their results will have on the future treatment landscape in MM.
(BELG J HEMATOL 2016;7(4):130–3)
Read moreBJH - volume 7, issue 4, september 2016
I. Moors MD
The state of the art in acute myeloid leukaemia (AML) in 2016 is changing dramatically. This is the result of the availability of new techniques for genome sequencing leading to understanding of the AML ontogeny at the molecular level, redefining minimal residual disease status in daily practice, the optimised use of induction and post-remission strategies and the introduction of many novel agents. Hopefully this will ultimately lead to the long expected improvement in survival for our individual patients.
(BELG J HEMATOL 2016;7(4):137–42)
Read moreBJH - volume 7, issue 4, september 2016
A. Janssens MD, PhD
(BELG J HEMATOL 2016;7(4):145–8)
Read moreBJH - volume 7, issue 4, september 2016
L. Zuurbier PhD
The standard of care is curative in the large majority of primary Hodgkin lymphoma (HL) patients and in approximately two-third of non-Hodgkin lymphoma (NHL) patients.1,2 Treatment strategies mainly consist of a combination of chemotherapy and radiotherapy.2 However, a substantial number of patients will develop relapsed or refractory (R/R) disease with poor prognosis. These patients often receive additional chemotherapy and stem cell transplantation (SCT).2 During the annual European Hematology association (EHA) conference, outcomes of various treatment regimes in lymphoma patients were discussed. In recent years, new agents for treatment of lymphoma were developed, including promising antibody-drug conjugates and inhibitors against programmed death 1 (PD-1) signalling. Results of clinical trials with these agents were presented at the EHA. Thus far, current treatment schemes are mainly dependent on clinical risk factors. Unfortunately, these treatment regimens coincide with many side-effects that affect the quality of life and morbidity of patients. To this end, personalised treatment needs further implementation and predictive and prognostic factors that can define patient-specific optimal therapies are therefore needed. These are currently under investigation and were also discussed at EHA 2016.
(BELG J HEMATOL 2016;7(4):151–7)
Read more
Top
